MetaCap

Benitec Biopharma (BNTC) vs Galectin Therapeutics (GALT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Benitec Biopharma (BNTC) has outperformed Galectin Therapeutics (GALT) over the past year, losing 40.3% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -85.7% for BNTC. Benitec Biopharma is the larger company by market cap ($285.9 million vs $271.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.31%GALT-49.72%
+26%-20%-65%
Nov 21, 20251 yearNov 20, 2026
BNTC-85.45%GALT0.00%
+144%+18%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus GALT key metrics
MetricBNTCGALT
Share price$7.92$2.69
Market cap$285.88M$271.35M
1-day change-2.76%-4.27%
YTD return-41.24%-35.34%
1-year return-40.31%-49.72%
5-year return-85.67%+4.67%
EPS (TTM)$-1.02$-0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-45.55M$-30.84M
52-week high$14.39$7.13
52-week low$7.72$2.03
Distance from 52-week high-45.00%-62.27%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+200.06%+308.92%
Average volume174.01K252.31K
Shares outstanding36.12M100.88M
Employees249
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

BNTC vs GALT FAQ

Which is bigger, Benitec Biopharma or Galectin Therapeutics?

Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $271.35M for Galectin Therapeutics (GALT).

Which stock has performed better over the past year, BNTC or GALT?

BNTC returned -40.31% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.

Are Benitec Biopharma and Galectin Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons